Document is current
Any future updates will be listed below
-
Authors
Lim, Yeong Jer
Duckworth, Andrew
Clarke, Kim
Oates, Melanie
Karpha, Indrani
Gornall, Matthew
Kalakonda, Nagesh
Slupsky, Joseph
Pettitt, Andrew
-
Funding
Funding for this research was provided by:
Medical Research Council (MR/N025989/1)
- License Information
-
More Information
Article History
Received: 11 March 2025
Accepted: 18 August 2025
First Online: 26 September 2025
Declarations
:
: AP has received research funding from BMS/Celgene, Gilead, GSK/Novartis and Roche. NK has sat on advisory boards for BMS/Celgene, Gilead/Kite, Hospira, Incyte/Morphosys, Janssen, Karyopharm, Roche, Takeda; and received research funding from BMS/Celgene, Gilead/Kite and Roche. All other authors declare no competing interests.
: Research Ethics Committee (REC) approvals were obtained for the collection and analysis of of CLL patients (REC ref. 19/NW/0573) and healthy controls (REC ref. 16/NW/0810). The study was performed in accordance with the Declaration of Helsinki and relevant ethical guidelines for research in humans, with written consent obtained from all patients.
